US Stem Cell Inc (USRM)

[Gsdubb]

Even ACTC (OCAT) has like $30,000 revenue for the last quarter I believe. I'm not knocking the science, but they are a phase 1 company essentially with over $200 million market cap. I sold all my shares of ACTC last summer when I found Bioheart...perhaps I will reinvest one day, but right now Bioheart is my gem. Bioheart's revenue increase is quite impressive and it doesn't even include the potential of Myocell down the road if and when an approval occurs IMO.